CGTN: Tibetan Religious Leader Extends Wishes for Spring Festival, Tibetan New Year
12.2.2021 16:50:00 EET | Business Wire | Press release
The Tibetan New Year falls on the same day as the Spring Festival this year. As a long, bitter winter starts petering down, colorful spring sneaks in.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210212005297/en/
Bainqen Erdini Qoigyijabu, the 11th Panchen Lama, on Friday expressed best wishes to all Tibetans at home and abroad for both the Spring Festival and the Tibetan Year of the Iron Ox through China Media Group (CMG) and China Tibet Online.
Looking back at the past year, he expressed his affirmation that China has overcome difficulties in the face of the pandemic. "The whole country united together, and all people worked with one heart, achieving outstanding results in preventing and controlling the COVID-19 pandemic, which draws much worldwide attention," he said.
"From the pandemic, we have further understood how precious life is. As I see it, health, peace and happiness are the most precious fortune in human life. From the pandemic, we have also further understood that all human beings are in a community with a shared future."
He also expressed his understanding of the importance of a community with a shared future for mankind.
Erdini Qoigyijabu spoke of the historic alleviation of poverty in Tibet and of people in the region living and working in peace and contentment, and expressed his sincere gratitude to the country. "I feel very gratified to see the new Tibet today," he said. "A glorious time and a happy homeland is not a gift from nature. We should remain grateful for our country, and for the thousands upon thousands of people willing to sacrifice for us.”
Finally, he offered New Year blessings to the people of the whole country. "Let us jointly wish and pray the world be peaceful, the country be prosperous, the people live in peace, the weather be favorable, and all living things live joyfully! I wish everyone and every family be happy, safe and sound in the New Year and reap a new harvest," he concluded.
The Tibetan New Year, known as Losar, is the most important festival on the Tibetan calendar.
Celebrating Losar, Tibetan New Year, on the plateau
Losar is roughly the same as the Spring Festival of the Han ethnic group.
The Tibetan New Year is calculated based on the Tibetan calendar. It starts on the first day of the first month of the Tibetan calendar and ends on the 15th day. It falls on February 12 this year.
Originally a harvest celebration, the festival gradually shifted to the beginning of a new year, after Princess Wencheng of the Tang Dynasty (618-907) married Songtsen Gampo, the then Tibetan King, and brought to the southwestern Chinese region the culture of the Han people.
For the Tibetans and those who have been exploring the Tibetan New Year on the plateau, Tashi delek, and Happy New Year!
A developing Tibet
Transportation has long been a bottleneck inhibiting Tibet's development, as the region is situated on the Qinghai-Tibet Plateau with complex geographical conditions for road construction and limited technology and funds.
Since late 2012, China has been bolstering its infrastructure investment in Tibet. So far, roads have connected 95 percent of the township-level administrations and 75 percent of the incorporated villages in the region. The road network in Tibet now stretches over 117,000 kilometers, up by 50 percent from the end of 2015.
As for air transportation, Tibet has launched a total of 130 air routes, with 61 cities connected by flights; 5.18 million passenger trips were registered in 2020.
The development of Tibet is well-founded with data.
With the strong support of the central government and the active assistance from the local people, the economy of Tibet has been developing steadily.
In 2018, Tibet registered a GDP growth rate of 10 percent, the highest in China.
According to the released work reports from the local governments in February 2021, Tibet led the 2020 growth rate among the country's 31 provincial-level regions, at 7.8 percent, followed by southwestern provinces of Guizhou and Yunnan, at 4.5 and 4 percent, respectively.
In 2021, Tibet's GDP growth target stands at over 9 percent, while the pace is set around 8 percent for Guizhou and Yunnan provinces.
Original article: here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210212005297/en/
Contact information
Media:
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
